tiprankstipranks
Trending News
More News >
LianBio Sponsored ADR (LIANY)
OTHER OTC:LIANY
US Market

LianBio Sponsored ADR (LIANY) AI Stock Analysis

Compare
62 Followers

Top Page

LI

LianBio Sponsored ADR

(OTC:LIANY)

Rating:45Neutral
Price Target:
LianBio's overall stock score is driven by its financial resilience due to strong cash reserves and equity position, but severely offset by its lack of revenue generation and persistent operational losses. The technical analysis indicates a bearish market sentiment, and the extremely low P/E ratio reflects market doubts about future profitability. The absence of significant earnings call data or corporate events means these factors do not influence the current score.

LianBio Sponsored ADR (LIANY) vs. SPDR S&P 500 ETF (SPY)

LianBio Sponsored ADR Business Overview & Revenue Model

Company DescriptionLianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
How the Company Makes MoneyLianBio generates revenue primarily through strategic partnerships and collaboration agreements with global pharmaceutical and biotechnology companies. The company acquires the rights to develop and commercialize promising drug candidates in specific Asian markets, particularly China. LianBio earns money through milestone payments, royalties on sales, and profit-sharing from successfully commercialized products. These partnerships allow LianBio to leverage existing research and development efforts while focusing on navigating the regulatory and market landscape of its target regions.

LianBio Sponsored ADR Financial Statement Overview

Summary
LianBio's financial statements reflect a company with strong cash reserves and equity positions but facing significant challenges in revenue generation and profitability. While recent improvements in cash flow are positive, the lack of revenue and consistent operational losses highlight the need for strategic shifts to ensure long-term viability.
Income Statement
15
Very Negative
The company has consistently reported zero revenue over the past five years, with increasing net losses year-over-year. Although there is a significant improvement in net income in the latest year, it does not reflect operational revenue performance but rather other gains that improved net results. The EBIT and EBITDA margins remain negative, indicating operational and financial challenges.
Balance Sheet
70
Positive
LianBio has maintained a strong equity base with a high equity ratio due to low levels of debt, which indicates financial resilience. However, the absence of revenue generation could pose future risks if the company continues to rely on cash reserves without generating income.
Cash Flow
60
Neutral
The company shows strong free cash flow and operating cash flow improvements in the latest year, indicating better cash management. However, the free cash flow growth rate is skewed due to prior negative cash flow, and the sustainability of this improvement remains uncertain without revenue.
BreakdownDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit-1.33M-1.00M-526.00K-76.13K0.00
EBITDA312.91M-109.49M-195.52M-134.90M-24.38M
Net Income311.14M-110.16M-196.56M-139.84M-24.37M
Balance Sheet
Total Assets617.96M319.96M426.33M279.29M43.88M
Cash, Cash Equivalents and Short-Term Investments567.37M302.36M383.24M254.35M43.30M
Total Debt2.46M4.34M4.83M1.88M532.00K
Total Liabilities36.77M26.31M39.01M27.57M3.69M
Stockholders Equity581.20M259.87M353.55M216.95M39.18M
Cash Flow
Free Cash Flow258.56M-100.91M-165.12M-99.20M-11.72M
Operating Cash Flow258.94M-99.07M-164.17M-98.31M-11.72M
Investing Cash Flow99.31M-69.12M-156.14M-887.52K0.00
Financing Cash Flow1.78M1.71M313.69M310.29M55.09M

LianBio Sponsored ADR Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.42
Price Trends
50DMA
0.32
Positive
100DMA
0.26
Positive
200DMA
0.27
Positive
Market Momentum
MACD
0.03
Positive
RSI
72.86
Negative
STOCH
73.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIANY, the sentiment is Positive. The current price of 0.42 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.32, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 72.86 is Negative, neither overbought nor oversold. The STOCH value of 73.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LIANY.

LianBio Sponsored ADR Risk Analysis

LianBio Sponsored ADR disclosed 114 risk factors in its most recent earnings report. LianBio Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

LianBio Sponsored ADR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
47
Neutral
$19.51M-167.57%127.51%71.16%
45
Neutral
$45.66M0.1453.53%
42
Neutral
$22.18M-99.84%10.23%
39
Underperform
$22.08M-134.15%95.48%
36
Underperform
$23.81M-39.78%84.17%
$6.40M-81.24%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LIANY
LianBio Sponsored ADR
0.43
0.12
38.71%
NNVC
NanoViricides
1.38
-0.37
-21.14%
TENX
Tenax Therapeutics
5.81
2.64
83.28%
CALC
CalciMedica
1.58
-2.66
-62.74%
LGVN
Longeveron
1.31
-0.42
-24.28%
CDIO
Cardio Diagnostics Holdings
3.68
-12.76
-77.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 25, 2025